Logo Image
News|Articles|March 15, 2016

Pharmaceutical Technology

  • Pharmaceutical Technology-03-15-2016
  • Volume 2016 eBook
  • Issue 1

Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry

The author discusses how x-ray spectrometry can be an effective way to measure these impurities and meet regulatory guidelines.

In sufficiently high concentrations, elemental impurities, typically from catalyst residue, can pose safety risks.  The author discusses how x-ray spectrometry can be an effective way to measure these impurities and meet regulatory guidelines.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.

Articles in this issue

over 10 years ago

Optimizing Tablet Compression

over 10 years ago

Excipient Quality and Selection

over 10 years ago

Filling the Analysis Gap in the Move to Continuous Processing

over 10 years ago

Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

over 10 years ago

Modeling and Simulation Move Downstream

over 10 years ago

Unifying Excipient Databases

over 10 years ago

Establishing a New Performance Standard for HPMC Capsules

Related to this article

View more
Regulatory Roundup—September 2026
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Read more
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
CPHI Milan 2026: Digital Supply Chains
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
Read more